Li et al. demonstrated the oncogenic function of TUC338 in DLBCL by sponging miR-28-5p, which leads to the activation of the EGFR/PI3K/AKT pathway [98]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.